This trial is an interventional, randomized, placebo-controlled, adaptive clinical trial in
outpatients with symptomatic microbiologically-confirmed SARS-CoV-2, in stable clinical
condition, and increased levels of serum C-reactive protein. The hypothesis of this study is
that early administration of prednisone for 7 days in patients with evidence of increased
C-reactive protein will decrease the progression of COVID-19, prevent clinical deterioration,
and hospital admission. Objectives: Primary Objective: To evaluate if early administration of
corticosteroids in non-hospitalized participants with proven SARS-CoV-2 infection with
compatible clinical symptoms and increased C-reactive protein can prevent hospital admission
or early death